Sharing a laboratory response does not make two drugs interchangeable. A 2008 study found that repeated amphetamine or pseudoephedrine exposure reduced a later drug-induced c-Fos response in rat brain. Separate tissue experiments showed that pseudoephedrine required much higher concentrations to inhibit dopamine uptake.
The findings support overlap in selected biological responses. They do not establish equal potency, equal effects in people, or a demonstrated risk of relapse from a particular human pseudoephedrine exposure.
What did “cross-tolerance” measure?
Ruksee and colleagues studied c-Fos, a protein used as an indicator of cellular response, in the striatum and nucleus accumbens of male Sprague-Dawley rats weighing 200–250 g. The endpoint was quantified staining of a 55-kDa band on Western blots of nuclear extracts.
Cross-tolerance meant that prior repeated exposure to one drug reduced the measured response to a subsequent challenge with the other. It did not mean that the animals were shown to tolerate every behavioral, cardiovascular or toxic effect of either drug.
Results were normalized optical-density measurements, expressed relative to a control value of 100%. They were not direct measurements of pleasure, dependence, drug seeking or impairment.
How were the rats exposed?
The eight-day repeated-treatment schedules used intraperitoneal injections twice daily. Pseudoephedrine doses increased from 25 to 30 to 35 mg/kg on days one through three, then remained at 40 mg/kg on days four through eight. D-amphetamine doses increased from 1 to 2 to 2.5 mg/kg, then remained at 3 mg/kg.
According to the methods, day-nine challenges used pseudoephedrine at 40 mg/kg, amphetamine at 3 mg/kg, or saline, with tissue collected 1.5 hours later. Figure 3’s caption contains an inconsistent challenge description in its amphetamine panel, referring to pseudoephedrine there as well. The methods provide the protocol account used here; that caption inconsistency should not be silently treated as a separate confirmed regimen.
These were injected rat exposures. They cannot be equated directly with oral human doses, tablet counts or blood concentrations.
What changed after repeated treatment?
Repeated pseudoephedrine treatment reduced the acute c-Fos response to pseudoephedrine in both brain regions. Prior amphetamine or pseudoephedrine exposure also reduced responses when the other drug was used as the final challenge, which the authors interpreted as cross-tolerance.
The cross-tolerance figure reports n=3 for each brain-region analysis. Tissue from two or three similarly treated animals was pooled to obtain sufficient material for nuclear extracts. Those small assay counts therefore should not be presented as three fully independent single-rat measurements or as a large behavioral cohort.
The reduced protein response was consistent with adaptation in pathways affected by both drugs. It did not identify every molecular step responsible for that adaptation.
Did the dopamine-uptake assay show equal potency?
No. In separate synaptosomal preparations from rat brain, both drugs inhibited uptake of radiolabeled dopamine, but amphetamine was substantially more potent.
For striatal preparations, the reported half-maximal inhibitory concentrations were 4.28 ± 0.47 micromolar for amphetamine and 667 ± 126 micromolar for pseudoephedrine. In nucleus accumbens preparations, they were 2.95 ± 0.42 and 530 ± 61 micromolar, respectively. Values were reported as means ± standard errors.
The corresponding potency differences were approximately 156-fold and 180-fold. The figure reports eight striatal and four nucleus-accumbens experiments, with duplicate samples within independent experiments. Technical duplicates do not double the independent experimental count.
These concentrations describe an isolated nerve-terminal preparation under laboratory conditions. They are not therapeutic ranges, human toxic thresholds or concentrations proven to produce equivalent experiences.
Was relapse or human addiction tested?
No. The authors discussed whether pseudoephedrine could reinstate drug seeking after prior stimulant exposure and proposed additional experiments. That possibility was a research question, not a result demonstrated by the c-Fos measurements.
The study did not administer the drugs to human participants, measure human drug liking, assess oral bioavailability or follow subsequent dependence outcomes. Historical statements about availability or regulation in the paper also do not establish current legal status.
How should the evidence be used?
The paper supports a precise statement: under its repeated intraperitoneal dosing protocols, the drugs showed cross-tolerance in a selected rat brain protein response, while differing greatly in potency in a separate dopamine-uptake assay.
Keeping those endpoints separate avoids replacing a measured cellular similarity with an unsupported claim of equal human effects. Neither cross-tolerance nor chemical similarity alone establishes an individual’s impairment, clinical risk or cause of an observed event.
Scientific source
Ruksee N, Tongjaroenbuangam W, Casalotti SO, Govitrapong P. Amphetamine and pseudoephedrine cross-tolerance measured by c-Fos protein expression in brains of chronically treated rats. BMC Neuroscience. 2008;9:99. doi:10.1186/1471-2202-9-99. Full text. Historical original rat and isolated-tissue experiments.
Leave a Reply